Rapport Therapeutics Says Bipolar Mania Drug Meets Phase 2 Primary Endpoint; Shares Rise

MT newswire2026/10/20 11:21

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

07:21 AM EDT, 10/20/2026 (MT Newswires) -- Rapport Therapeutics (RAPP) shares rose more than 29% in Tuesday premarket trading after the company said its experimental drug RAP-219 met the primary endpoint in a phase 2 trial for acute bipolar mania. The company said the drug achieved a 3.1-point placebo-adjusted improvement in the Young Mania Rating Scale at week 3. RAP-219 was generally well-tolerated, with no serious adverse events reported during the three-week treatment period, the company said. Rapport Therapeutics said it plans to meet with the Food and Drug Administration in Q1 2027 to discuss the data and that two phase 3 trials expected to begin in H2 2027.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

In September, Anthropic directly acquired Caterpillar equipment orders worth 3.4 billion USD, securing 1.7 GW of gas generator units, marking the largest single purchase of power generation equipment in AI history. This move bypassed utility middlemen, capturing scarce capacity at prices set years ago with near-term delivery. It is part of Anthropic's plan to invest over 895 billion USD in computing infrastructure by 2045.

华尔街见闻•2026/11/08 12:41